TickerFacts.

Senti Biosciences Holdings, Inc. (SNTI): Revenue

Annual figures by period end, from SEC filings.

$22.0K
Year ended 2025-12-31
$55.0K
Trailing 12 months to 2026-06-30
-81.2%
3-year compound annual growth
$3.29M2021-12-31: $2.29M2022-12-31: $3.29M2023-12-31: $1.98M2024-12-31: $02025-12-31: $22.0K$22.0K
2021-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$22.0Kn/a2026-03-27, From 2025-01-01
2024-12-31$0-100.0%2026-03-27, From 2024-01-01
2023-12-31$1.98M-39.8%2025-03-20, From 2023-01-01
2022-12-31$3.29M+43.4%2024-03-21, From 2022-01-01
2021-12-31$2.29Mn/a2023-03-22, From 2021-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Senti Biosciences Holdings, Inc. (SNTI)2025-12-31$22.0Kn/a
Entera Bio Ltd. (ENTX)2025-12-31$42.0K-76.8%
Inmune Bio, Inc. (INMB)2025-12-31$50.0K+257.1%
Creative Medical Technology Holdings, Inc. (CELZ)2025-12-31$6.0K-45.5%
AIM ImmunoTech Inc. (AIM)2025-12-31$88.0K-48.2%
VivoSim Labs, Inc. (VIVS)2026-03-31$131.0K-9.0%
Zivo Bioscience, Inc. (ZIVO)2024-12-31$157.2K+468.6%
aTYR PHARMA INC (ATYR)2025-12-31$190.0K-19.1%
Cardiff Oncology, Inc. (CRDF)2025-12-31$593.0K-13.2%

Compare SNTI, ENTX, INMB, CELZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗